Q2FY24 Quarterly Result Announced for Procter & Gamble Health Ltd.
Pharmaceuticals company Procter & Gamble Health announced Q2FY24 results: In a challenging operating environment, the company reported sales of Rs 304 crore, at par vs a year ago. The Profit After Tax (PAT) for the quarter was Rs 72 crore, down 6% vs year ago, owing to one-time items in the quarter. Excluding this one-time impact, Profit After Tax (PAT) was up by 2% vs a year ago. Milind Thatte, Managing Director, P&G; Health India, said, “This has been a challenging quarter for the Company on account of an overall slowdown in the Vitamins, Minerals and Supplements category coupled with a delayed seasonal onset. The team continued to stay resilient. With improved productivity, efficiency and continued strategic investments, we have been able to deliver a modest topline and bottom-line. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy combined with our operational agility will help us navigate the mid-term and deliver balanced growth.” Result PDF06-02-2024